Shionogi sets up US drug discovery venture
This article was originally published in Scrip
Shionogi has set up a new US-based joint venture to conduct basic drug discovery and biomarker research. Ezose Sciences is based in New Jersey and is 87%-owned by the Japanese drug company. Sumitomo Bakelite, a diversified Japanese materials company, holds the remainder. The new operation will provide high-throughput services designed to identify disease-related proteins, using glycan and glycoprotein markers to determine the structure of the parent protein.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Japanese major builds presence in novel device technology beyond its conventional therapeutics as looks towards a more holistic future of care.